• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

State of Cancer Control in South America: Challenges and Advancement Strategies
Hematol Oncol Clin North Am. 2023 Jun 21:S0889-8588(23)00068-0. doi: 10.1016/j.hoc.2023.05.013. Online ahead of print.ABSTRACTCancer is a major public health problem in South America. The cancer mortality burden is increasing in the region due to its presentation at later stages, which is related to limited access to cancer care. This results in a noticeable inequity in provisions of cancer care including specialized screening programs, as well as cancer-related treatments such as personalized medicine, radiation therapy, palliative care, and survivorship services. Consequently, South America faces many challenges for canc...
Source: Cancer Control - June 23, 2023 Category: Cancer & Oncology Authors: Ivy Riano Ana I Velazquez Lucia Viola Inas Abuali Kathya Jimenez Oyepeju Abioye Narjust Florez Source Type: research

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
We report 2-year toxicity findings from PACE-B, a randomised trial of conventionally fractionated or moderately hypofractionated radiotherapy versus SBRT.METHODS: PACE is an open-label, multicohort, randomised, controlled, phase 3 trial conducted at 35 hospitals in the UK, Ireland, and Canada. In PACE-B, men aged 18 years and older with a WHO performance status 0-2 and low-risk or intermediate-risk histologically-confirmed prostate adenocarcinoma (Gleason 4 + 3 excluded) were randomly allocated (1:1) by computerised central randomisation with permuted blocks (size four and six), stratified by centre and risk group to contr...
Source: Cancer Control - September 16, 2022 Category: Cancer & Oncology Authors: Alison C Tree Peter Ostler Hans van der Voet William Chu Andrew Loblaw Daniel Ford Shaun Tolan Suneil Jain Alexander Martin John Staffurth John Armstrong Philip Camilleri Kiran Kancherla John Frew Andrew Chan Ian S Dayes Aileen Duffton Douglas H Brand Dan Source Type: research

Spectrum of National Institutes of Health-Funded Research in Cardio-Oncology: A Basic, Clinical, and Observational Science Perspective
Heart Fail Clin. 2022 Jul;18(3):515-528. doi: 10.1016/j.hfc.2022.01.001.ABSTRACTAdvances in cancer treatments have led to nearly 17 million survivors in the US today. Cardiovascular complications attributed to cancer treatments are the leading cause of morbidity and mortality in cancer survivors. In response, NCI and NHLBI held 2 workshops and issued funding opportunities to strengthen research on cardiotoxicity. A representative portfolio of NIH grants categorizing basic, interventional, and observational projects is presented. Compared with anthracyclines, research on radiation therapy and newer treatments is underrepres...
Source: Clinical Lung Cancer - June 19, 2022 Category: Cancer & Oncology Authors: Bishow B Adhikari Scarlet Shi Eileen P Dimond Nonniekaye Shelburne Patrice Desvigne-Nickens Lori M Minasian Source Type: research

NIDCR's Fall 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Fall 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   NIDCR News 5 Q&As About “Oral Health in America: Advances and Challenges” NIDCR issued a brief Q&A regarding details of the forthcoming report Oral Health in America: Advances and Challenges, which will be published in Fall 2021. This comprehensive report will examine improvements in oral health over the past two decades,...
Source: NIDCR Science News - September 1, 2021 Category: Dentistry Source Type: news

Basket Trials for Intractable Cancer
This study has made a significant impact on clinical practice in cancer patients harboring the TRK translocation, and also illustrates the potential for future advancements in drug development and clinical trials of cancers harboring rare genomic alterations (50). Second, a basket trial may allow screening for potential efficacy across multiple tumor types in order to guide more traditional, disease-specific, follow-up studies. The goal of some basket trials is to obtain an overall assessment of the drug with pooled histologies; in such trials, subsequent analyses are straightforward, and are comparable to those in standa...
Source: Frontiers in Oncology - April 11, 2019 Category: Cancer & Oncology Source Type: research

Next-Generation Cancer Immunotherapy Targeting Glypican-3
This study was supported in part by the National Cancer Center Research and Development Fund (25-A-7 and 28-A-8); Health and Labor Science Research Grants for Clinical Research, Japan; and joint research funding from Takeda Pharmaceutical Co, Ltd.; Noile-Immune Biotech Inc.; Ono Pharmaceutical Co., Ltd.; BrightPath Biotherapeutics Co., Ltd.; and Sysmex Co., Ltd. This study was performed as part of a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan. Conflict of Interest Statement TN, TS, and TY ...
Source: Frontiers in Oncology - April 9, 2019 Category: Cancer & Oncology Source Type: research

Top Artificial Intelligence Companies in Healthcare to Keep an Eye On
The field of medical AI is buzzing. More and more companies set the purpose to disrupt healthcare with the help of artificial intelligence. Here, I collected the biggest names currently on the market ranging from start-ups to tech giants to keep an eye on in the future. Artificial Intelligence has to and will redesign healthcare No one doubts that artificial intelligence has unimaginable potential. Within the next couple of years, it will revolutionize every area of our life, including medicine. Although many have their fears and doubts about AI taking over the world, Stephen Hawking even said that the development of full ...
Source: The Medical Futurist - January 31, 2017 Category: Information Technology Authors: nora Tags: Artificial Intelligence in Medicine Healthcare Design AI big data digital health drug development GC1 genetics healthcare companies Innovation medical imaging Personalized medicine pharma Source Type: blogs

Fight Aging! Newsletter, June 6th 2016
This study teaches us that poor wound healing and wrinkling and sagging that occur in aging skin share similar mechanisms." Reduced cell cohesiveness of outgrowths from eccrine sweat glands delays wound closure in elderly skin Human skin heals more slowly in aged vs. young adults, but the mechanism for this delay is unclear. In humans, eccrine sweat glands (ESGs) and hair follicles underlying wounds generate cohesive keratinocyte outgrowths that expand to form the new epidermis. Our results confirm that the outgrowth of cells from ESGs is a major feature of repair in young skin. Strikingly, in aged skin, ...
Source: Fight Aging! - June 5, 2016 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Finding Common Ground in the Search for Better Patient Care and Outcomes
By JOE V. SELBY, MD A basic rule of scientific discovery is that the answers you get are only as good as the questions you ask. That is certainly the case in health care. Traditionally, it has been the sole responsibility of health researchers to develop questions for study that, when answered, can provide reliable and relevant information for patients and clinicians. For the most part, they’ve done an exceptional job, as evidenced by countless discoveries about the nature of disease and remarkable advances in diagnosing, preventing and treating them. But when researchers are the only ones determining scientific inquiry,...
Source: The Health Care Blog - October 7, 2015 Category: Consumer Health News Authors: Simon Nath Tags: THCB Source Type: blogs

Senolytic Drugs to Kill Off Senescent Cells and Thereby Slow the Progression of Degenerative Aging
As we age, an increasing number of cells fall into a senescent state in which they cease dividing and begin to secrete all sorts of compounds that both harm surrounding tissue structure and raise the odds of nearby cells also becoming senescent. This seems to be a tool of embryonic development that now also acts to suppress cancer risk by removing the ability to divide from those cells most likely to become cancerous. Unfortunately it harms tissue function in doing so, and worse, only actually suppresses cancer risk when there are comparatively few senescent cells. Given a lot of these cells their activities cause chronic ...
Source: Fight Aging! - March 9, 2015 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs